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Introduction
Gay, bisexual, and other men who have sex with men (GBMSM) continue to disproportionately bear the burden of the epidemic. 1, 2 There is an urgent need for effective biomedical and behavioral strategies to reduce incidence in this population. In 2012, the FDA approved the use of once-daily Truvada (Emtricitabine/Tenofovir) for use among HIV-negative individuals as HIV Pre-Exposure Prophalyxis (PrEP), and the CDC subsequently recommended combined once-daily Truvada to be coupled with traditional HIV prevention/education (e.g., condom use). [3] [4] [5] PrEP is, at present, one of the most promising biomedical prevention tools for GBMSM in the US.
Daily dosing may not be necessary for all PrEP candidates. First, most individuals are not exposed to HIV on a daily basis and Truvada has a relatively long half-life in plasma and peripheral blood mononuclear cells (≥60 and 39 hours). 6, 7 This suggests less frequent dosing might maintain sufficient levels to prevent infection in the event of an exposure. In fact, results from the iPrEx Open Label Extension (OLE) study-a PrEP demonstration project-found no new HIV infections among those who took Truvada at least 4 days per week. 8 Second, daily dosing, compared with less frequent dosing, might be considered burdensome in several ways, including the physical act of swallowing the pill, the cognitive burden of remembering daily, the potential for increased treatment side effects or toxicity, and the financial costs. [9] [10] [11] As data from animal models regarding the efficacy of intermittent PrEP are promising, 12, 13 two intermittent PrEP dosing strategies are being studied in humans as alternatives to daily dosing-time-driven and event-driven dosing. In the HPTN 067 (ADAPT) study, daily dosing is being compared to both time-driven and event-driven dosing. The timedriven arm involves one dose of Truvada taken twice weekly regardless of sexual activity and an
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additional post-exposure dose after any sexual act; the event-driven arm in the ADAPT trial involves one dose 24-48 hours before sexual intercourse and a second within two hours of intercourse. 14 In the IPERGAY trial, 15 a different form of event-driven dosing is utilized-two doses of Truvada are taken 2-24 hours before any anticipated sexual intercourse and, if sexual behavior occurs, two doses are taken with the first occurring 24 hours and a second 48 hours after sexual activity. On October 29, 2014, the IPERGAY study announced that preliminary results examined by their Data Safety Monitoring Board indicated a significant difference in HIV incidence between those receiving event-driven dosing and placebo, and closed the placebo arm. 16 This suggests that event-based dosing may soon be among the recommended PrEP strategies, particularly since a recent study of potential PrEP users in Kenya found no differences in preferences for daily versus event-driven regimens. 11 Although the full extent of the efficacy of intermittent dosing will not be known until these trials are completed, effectiveness of eventdriven dosing will likely depend on the ability of individuals to predict in advance when sex will occur.
There are important caveats to intermittent PrEP dosing strategies. Individuals who typically experience three or more exposures in a given week might be better served by daily PrEP. 17 Similarly, event-driven PrEP requires individuals to dose shortly following the time that exposure occurs. In a study of GBMSM and female sex workers, adherence rates for daily dosing (83%) were significantly higher than for intermittent dosing (55%) and dosing after sex (26%), 9 and similar findings emerged in a study of HIV serodiscordant couples in Uganda. 18 However, preliminary results from the IPERGAY trial suggest high adherence to intermittent dosing, with participants on average taking 15 doses per month. 19 6
There is little research to suggest whether GBMSM can accurately predict when sexual events will occur. In a study of 1,013 U.S. men online, Volk et al. 17 reported that 50.4% of GBMSM had no advanced planning prior to their last sexual encounter, and 8.2% reported planning only minutes in advance. The remaining men reported planning hours (22.4%), 1-3 days (10.7%), or more than 3 days in advance (8.4%). Similarly, in a study of 823 GBMSM in Bangkok, Thailand, men reported that more than two-thirds of their sex events from the previous week were planned, though how far in advance men planned the events was not reported. 20 Both studies suggested some men were able to plan sexual events in advance. However, these analyses relied upon retrospective recall data potentially overestimating the extent to which individuals were able to predict their own behavior.
Addressing these limitations, the present study was designed to use prospective (i.e., daily diary) analyses to examine the accuracy of GBMSM in predicting the next day's sexual behavior for the purposes of informing future research on alternative PrEP dosing schedules. Our sample included GBMSM who reported high numbers of sexual partners-a group explicitly targeted in CDC guidelines for PrEP utilization. 21 Our a priori assumption is that the most important classification statistic to minimize is false negatives-where the individual believes they will not have sex the next day and does not take a PrEP dose, but ultimately has sex on the next day. A secondary classification priority was avoiding medication waste by taking it unnecessarily the day before sex does not occur (i.e., precision).
Method
Analyses were conducted on data from The Pillow Talk Project, a study of highly sexually active (i.e., ≥ 9 male partners in 90 days) gay and bisexual men (GBM) in New York
City. 22, 23 The analyses were limited to the 208 men confirmed to be HIV-negative with a rapid 7 HIV test. One man did not complete any of the daily diaries and was excluded from analyses.
We did not implement the question that is the main focus of these analyses until July, 2012. As such, 115 men never received this question. This resulted in a sample of 92 men with an average completion rate of 78.1% (M = 23.4 days) and median rate of 86.7% (Mdn = 26.0 days).
Analyses involved the creation of a time-lagged variable and as such, contiguous reporting was required (see "daily diary measures"). In all, 341 days' worth of data were unmatched, resulting in a final analytic dataset of 1,688 days across 92 HIV-negative, highly sexually active GBM.
Participants and Procedures
Potential participants completed a phone-based screening to assess eligibility, which was defined as: 1) at least 18 years of age; 2) biologically male and self-identified as male; 3) nine or more male sexual partners in the prior 90 days; 24-28 4) self-identification as gay, bisexual, or some other non-heterosexual identity; and 5) daily access to the Internet. Participants who met preliminary eligibility were emailed a link to an Internet-based computer-assisted self-interview (CASI), which included informed consent procedures. Men completed this one-hour survey at home followed by an in-person baseline appointment. Final eligibility and enrollment was confirmed during the in-person appointment, with sexual partner criteria confirmed using a timeline follow-back (TLFB) interview. Following the baseline, participants received a unique link to complete their diaries each night for 30 days. All procedures were approved by the Institutional Review Board of the City University of New York.
Measures
Online CASI measures. Participants were asked to report demographic characteristics, including sexual identity, age, race/ethnicity, education, and relationship status.
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Daily diary measures. The diary measure was based on previous studies conducted with GBM. [29] [30] [31] Each day, participants reported on their substance use and we calculated one indicator
(1 = yes, 0 = no) of whether the participant had consumed five or more alcoholic drinks (i.e., heavy drinking) and a second for whether they had used cocaine, crack, crystal meth, ecstasy, heroin, ketamine, or GHB (i.e., club drugs). Following those sections, participants were asked whether they had engaged in any sexual activity with another person and, if so, were asked a series of questions for each partner they reported for that day. For the purposes of these analyses, we recoded all partner-level data into a single day-level indicator of whether or not (1 = yes, 0 = no) the participant had engaged in any anal sex with a casual male partner. At the end of the survey, participants were asked, "How likely is it that you will have anal sex with a casual male partner tomorrow?" and were given a visual analog-style sliding scale ranging from 0 (absolutely sure I will not) to 100 (absolutely sure I will). This variable was time-lagged such that it was matched with the sexual behavior report on the next day to estimate their accuracy in prediction.
The variable was also centered at 50 and divided by 10 such that a one-unit increase corresponded to an increase of 10% in self-reported likelihood.
Analytic Plan
All models were conducted using multilevel logistic regression accounting for a firstorder autoregressive (i.e., AR1) structure in the repeated responses and a random intercept with an unstructured covariance matrix using SAS version 9.2's GLIMMIX procedure. 
Results
As shown in Table 1 , the sample was diverse with regards to race/ethnicity, employment status, and educational achievement, while a majority was gay-identified and single.
Additionally, nearly two-thirds of the sample engaged in sexual activity on three or more days per week. [ Table 1 Here]
[ Figure 1 Here]
We tested for linearity of the association between self-reported likelihood and behavior by creating 11 dichotomous indicators of each decile on the likelihood variable (e.g., 0%, 1-10%, 91-100%) and examining their association with behavior. As can be seen in Figure 1 , the association was primarily linear. We also explored this issue using both first-order and quadratic terms predicting the behavioral outcome and found no evidence of a significant quadratic effect.
As such, further analyses were conducted examining a linear association between likelihood reports and behavior. In a model with only the continuous likelihood rating, the odds of sex on an average day with a 50% likelihood rating was 0.30 (probability = 0.23) and this increased by 36% (OR = 1.36) for every 10% increase in self-reported likelihood. We found that the effect of time (i.e., the day of diary completion) did not have an influence on the outcome, but that weekend days (i.e., Friday, Saturday, Sunday) versus weekdays were associated with increased odds of anal sex with casual partners (OR = 1.31, 95%CI [1.00, 1.72]). We found no evidence of an interaction between likelihood ratings and whether or not it was a weekend day. That is, though men tended to be more sexually active on the weekends, this neither improved nor worsened their accuracy of prediction. As a result of its significant main effect, we subsequently adjusted all models for whether or not the day on which the behavior was measured on a weekend day.
In the next series of multilevel models, we separately tested level 1 (i.e., daily) substance use variables for main effects on the outcome as well as interaction effects with the likelihood rating to examine whether certain contextual effects might influence the accuracy of participants'
reports. were no levels of self-reported likelihood where participants had good precision in their predictions; even at a cutoff of 100%, doses would be unnecessary 41.4% of the time that they were taken.
Discussion
Based on our results, there appear to be two approaches that could be used to inform event-driven intermittent PrEP use among GBMSM where a dose needs to be taken a day prior to sex. The first strategy would counsel individuals to "Take a dose today unless you are not going to have sex tomorrow." Under this strategy, classification statistics suggest a recommended a 1% or greater chance of sex the next day be used; in other words, individuals would be instructed to only skip a daily dose when they were certain there would be no chance of having sex the next day. In this sample, the 0% likelihood value produced a rate of 3.8% false negatives (i.e., cases where sex was not predicted but did occur the next day). Although a 0% chance of sex may seem like a very stringent criterion, it has a number of beneficial properties beyond the important characteristic of minimizing false negatives. This value was the most common prediction point-even in this sample of highly sexually active men-with participants reporting 0% likelihood an average of 4.2 days per month. In our sample, this means that 14% of doses could have been skipped without increasing risk for transmission in the proceeding 24
hours. At an estimated cost of $25.86 per dose, 32 this would save an average of $1,321.45 per year in medication costs per participant (i.e., more than 1.5 months' worth of medication). Given known innumeracy issues in individuals' ability to interpret probabilities, 33 and the fact that men 12 were better at predicting when they would not have sex than when they would, another beneficial feature of this cut point is that it is easy to apply (i.e., "only skip a dose if you are certain there is no chance you will have sex tomorrow") versus an intermediate value. Perhaps most importantly, the consequence of making a wrong decision under this strategy are rather benign (i.e., an unnecessary dose is taken).
A second potential counseling strategy for those on event-driven dosing would be to focus on sexual forecasting, working with GBMSM to identify which days of the week they are likely to have sex and instruct them to "Take a dose if there is any chance you are going to have sex the next day." This is similar to the counseling approach being used in HPTN 067 (ADAPT) and will be effective when users can have high precision in their predictions at the same time as avoiding false negatives. However, our study suggests that, among highly sexually active GBM, this approach would not be effective because classification statistics indicate the men had low levels of precision in predicting their sexual behavior across the full range of likelihood ratings (15.5% -58.6%). Even at a reported 100% likelihood of sex occurring the next day, precision was only 58.6% and the false negative rate was unacceptably high at this likelihood level (i.e., 94%). Most importantly, the consequences of making a wrong decision under this strategy are high (i.e., a necessary dose would not be taken, therefore increasing risk of infection).
[ Table 2 Here] Importantly, our findings also suggest that the fixed dosing schedule may be the most appropriate for men who have at least one sexual event per week. Table 2 contains a hypothetical week for the ADAPT and IPERGAY trial dosing schedules based on sexual behavior. As can be seen, the fixed dosing schedule in ADAPT would lead to a greater number of doses than the other two schedules only during weeks when no sexual activity is anticipated or occurs (within the table, perfect correspondence between prediction and behavior is assumed). In contrast, the IPERGAY event-driven dosing schedule may lead to as many as eight doses in a week with only two anticipated and actual sex events, which is more than the number of doses taken with daily
PrEP. The event-driven dosing in ADAPT and IPERGAY is contingent upon successfully predicting one's sexual behavior such that a pre-coital dose can be taken-in ADAPT's eventdriven dosing, a single dose is taken between 24-48 hours prior to sexual activity while IPERGAY's event-driven schedule calls for two doses taken 2-24 hours prior to sexual activity. Table 2 assumes perfect correspondence between anticipated and actual sexual behavior, which the current study demonstrated is rarely the case. Rather, our findings demonstrate that, in general, attempting to make a prediction approximately 24 hours in advance led to very imprecise estimates and would ultimately lead to pre-coital doses being taken on all but approximately one day per week, on average. In contrast to this, the IPERGAY schedule, while requiring a greater number of pre-coital doses (i.e., 2 pills rather than one), could ultimately result in fewer doses per week if participants are more accurate at predicting sex within shorter intervals of time (i.e., the 2-24 hours recommended in the IPERGAY schedule). Although this is not depicted within the table due to the complexity, this may result in fewer pre-coital doses being taken due to greater accuracy in predicting sex at shorter intervals, though it would result in more doses being taken after actual engagement in sexual behavior.
Overall, it is impossible to say with the current data which dosing schedule will lead to the most adaptive plan due to the fact that all estimates were requested on the day prior rather than on the day of a sexual event as would be possible within the IPERGAY schedule. More information is required about the potential increases in accuracy at these shorter intervals to determine how many pills could ultimately be skipped safely and what the resultant cost savings 14 would be. These data are not able to shed light on the potential efficacy of any of these dosing schedules. However, the data do suggest that men would meet the level of 4 doses per week with only one sexual event per week in IPERGAY and with two sexual events in the fixed dosing schedule of the ADAPT trial, though they may not receive a minimum of four doses at two sexual events per week using the event-driven dosing in ADAPT, depending on the distance between sexual events as can be seen in the final two hypothetical weeks in Table 2 . Given that recent research suggests that four doses may be optimal for preventing infection, 8 and the recent discontinuation of the placebo arm in the IPERGAY trial suggesting efficacy of event-driven dosing, 16 our data suggest that men who have one to two sexual events per week may be best advised by the IPERGAY event-driven dosing schedule given both its flexibility with pre-coital prediction intervals and the number of doses that would be achieved. However, for men for whom sexual behavior is more regular, the IPERGAY schedule may lead to more doses than would be required by daily PrEP and these men may be better suited to utilize the fixed ADAPT event-driven dosing schedule combined with the suggestion from these data that they take a precoital dose unless they believe there is no chance of sexual behavior on the following day. These results may lead to both the optimal dosing levels and cost savings.
In addition to informing strategies for how to counsel event-driven PrEP users on how to predict sex and adjust their dosing, this study also provided novel information on how well men could predict their future sexual behavior. In this sample of highly sexually active GBM, participants consistently overestimated the likelihood that sex would occur across the range of likelihoods. For example, when men predicted between 71-80% likelihood of having sex, the actual probability was 45.7%. In the absence of data on such predictions among GBM who are less sexually active, it is unknown if this represents a general affirmative bias among GBM (or Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 5 men in general), or whether the characteristics of this study population may moderate prediction tendency. For example, highly sexually active men may be more likely to predict sex will occur due to their higher overall frequency of sex. Other important findings included the lack of effect moderation due to weekend versus week day or substance use during sex; although both increased the probability of having sex, they did not decrease men's accuracy of prediction. This suggests that GBM may have accounted for these variables in their predictions of the likelihood of sex occurring.
This study is not without limitations. First, this was a sample of highly sexually active GBM in NYC, and therefore results may not generalize across the distribution of sexual activity levels. At the same time, the population is one of the primary targets for PrEP utilization, 21 and therefore our findings have particular relevance. Second, it is important to note that the data came from an observational diary study and participants had no incentive to change their sexual behavior based on their predictions. In the case of event-driven PrEP, users may have an incentive to change their behavior depending on if they predicted sex and therefore took a PrEP dose on the prior day. These changes could include avoiding sex when a dose was not taken in advance, which would decrease false negatives, increasing condom use when a dose was not taken the prior day, or being more inclined to engage in sex on days after a dose was taken, which would increase the precision of their predictions. To the extent that this strategy of eventdriven intermittent PrEP dosing is effective at preventing HIV infection, then such an increase would be inconsequential. Lack of effectiveness, however, would produce negative consequences akin to risk compensation. 34 Finally, the sample size was limited to fewer than 100 men, and thus we lacked power to examine many potential individual-level moderators of prediction accuracy, including level of risk. Moreover, the likelihood question, and thus the outcome examined, focused only on sex with casual partners. Future studies are needed that more carefully examine which individual characteristics make men better or worse at accurately predicting their behavior and incorporate the role of relationships within the analyses.
In conclusion, our unique daily diary data allowed for estimation of how well highly sexually active GBM can predict when sex will occur on the next day. Such data have been missing from the discussion of event-driven intermittent PrEP utilization. On an a priori basis we concluded that the most important classification statistic to minimize was false negatives, as they would serve to increase risk for infection because a needed dose it not taken. Our diary data indicated there were very few false negatives when participants indicated there was 0% chance of sex occurring the next day, and therefore suggest that the most effective approach for this population is to advise that a dose should be taken every day, unless the user is certain that sex will not occur the next day. This recommendation is essentially equivalent to daily PrEP minus days in which sex is not going to occur the next day. In the diary data there were many such days, and therefore this approach could produce considerable cost savings, which is critical because existing analyses indicate cost-effective implementation of daily PrEP would be challenging in the U.S. 32, 35, 36 . It is also expected that less frequent dosing would decrease sideeffects related to drug exposure, 21 which could impact adherence. Given these benefits of eventdriven PrEP, future trials of this event-driven intermittent usage strategy are likely to be conducted if the results of current trials support efficacy. If our results are replicated in further studies, future event-driven PrEP trials may be able to increase efficacy by shifting their counseling strategy to one of "take a dose unless you are certain there is no chance sex will occur tomorrow." Such strategies may lead to even greater cost savings among men with less frequent sexual activity. 
